Key message
Chronic HCV infection can be treated well with the help of direct antiviral drugs. However, these drugs have only been on the market for a short time, so it is difficult to estimate to what extent viral resistance will require the development of new drug classes.
Translational perspective
Banda and colleagues have explored the mechanism of action of HCV fusion inhibitors - a new class of anti-HCV drugs - and identified improved drug candidates. They show where the drugs attack the virus and which viral properties confer resistance to fusion Inhibitors.